Get the Stockscreener App
1.37
0.00%
0.00
After Hours:
1.37
Biovie Inc stock is traded at $1.37, with a volume of 75,559.
It is up +0.00% in the last 24 hours and down -29.38% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.37
Open:
$1.36
24h Volume:
75,559
Relative Volume:
0.48
Market Cap:
$10.33M
Revenue:
-
Net Income/Loss:
$-19.92M
P/E Ratio:
-0.3207
EPS:
-4.2716
Net Cash Flow:
$-20.51M
1W Performance:
-3.86%
1M Performance:
-29.38%
6M Performance:
+13.22%
1Y Performance:
-81.68%
1-Day Range:
$1.35
$1.43
1-Week Range:
$1.26
$1.49
52-Week Range:
$1.06
$7.7493
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.37 | 10.33M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BIVI|BioVie Inc|Price:1.400|Chg%:+0.030 - TradingKey
BIVI|BioVie Inc|Price:1.370| - TradingKey
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
BioVie Inc (BIVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioVie Inc. Revenue Breakdown – NASDAQ:BIVI - TradingView
BIVI|BioVie Inc|Price:1.370|Chg%:-0.070 - TradingKey
BioVie Warrants (BIVIW) Hold Steady at $0.53 Amid Tight Trading RangeStrangle Setup - dars.gov.et
Why Eva Live Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Sahm
Daily Brief Health Care: JPJ (TCM) Limited(TCM), Abeona Therapeutics , Mani Inc, BioVie , Propanc Biopharma, Tivic Health Systems Inc and more - Smartkarma
IPO Databook: Biovie (BIVI US)Jul 2026 - Smartkarma
BioVie Files for a Stock Offering - Moomoo
[S-1] BIOVIE INC. Files IPO Registration Statement - Stock Titan
BIVIW SEC FilingsBiovie Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enterprise value to EBIT forward of BioVie Inc. – NASDAQ:BIVIW - TradingView
บทสัมภาษณ์ของ Foremost Clean Energy และ BioVie เตรียมออกอากาศในรายการ RedChip Small Stocks, Big Money(TM) ทางสถานีโทรทัศน์ Bloomberg TV - Moomoo
BioVie Inc. Warrants (BIVIW) Trade Flat Near Key Levels – What to WatchHedge Fund Favorites - dars.gov.et
BioVie Inc Warrant 2025-01.06.30 on BioVie Financial Disclosures & SEC Filings - TradingView
Price to earnings forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Price to sales forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Price to book forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Enterprise value to revenue forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Enterprise value to EBITDA forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Enterprise value to EBIT forward of BioVie Inc. – NASDAQ:BIVI - TradingView
BioVie Inc. Class A Financial Disclosures & SEC Filings - TradingView
[EFFECT] BIOVIE INC. SEC Filing - Stock Titan
BioVie Inc. (BIVI) Climbs 3.6% as Shares Test Key Resistance Near $2.11Opening Range Breakout - dars.gov.et
BioVie Inc. Class A Actuals & Estimates (NASDAQ:BIVI) - TradingView
BIVI Q1 2026 Earnings: EPS Beats Estimates as Drug Development ProgressesEarnings Per Share - dars.gov.et
BioVie | 4: Statement of changes in beneficial ownership of securities-Officer DO CUONG V - Moomoo
BIVI Forecast — Price Target — Prediction for 2027 - TradingView
BIVI Q1 2026 Earnings: EPS Beat on Narrower-Than-Expected Loss; Stock Slightly DownEarnings Momentum Score - dars.gov.et
BioVie Inc. Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances PipelineQuarterly Financial Update - DonanımHaber
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioVie Inc. (BIVI) Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesRevenue Growth Report - dars.gov.et
Biovie Files To Offer Up To $300 Million In SecuritiesSEC Filing - TradingView
BioVie (NASDAQ: BIVI) files $300M shelf registration to sell securities - Stock Titan
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Institutional Confidence - TradingKey
BioVie Inc (BIVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIVI Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating ExpensesAdjusted Earnings Analysis - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss Than Expected as Pipeline Progress ContinuesEnergy Earnings Report - newsline.com
BIVI Q1 2026 Earnings: EPS Beat Amid Clinical Progress; Stock DeclinesShare Repurchase Impact - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareh - GuruFocus
Law firm investigates BioVie officers for possible breach of duties to shareholders - Pluang
BioVie Inc. (BIVI) Q1 2026 Earnings: EPS Surpasses Estimates Despite Ongoing Revenue VoidEarnings Call Highlights - newsline.com
BIVI Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines on No Revenue StreamTrough Earnings Signal - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Barchart.com
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):